Shattuck Labs Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Shattuck Labs Inc 's ROA in the second quarter of 2026?
Shattuck Labs Inc recorded a cumulative net loss of $-53 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -40.88%.

However, within the Healthcare sector 495 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3987, from total ROA ranking in the first quarter of 2026 at 4684.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	243.15 %	32.34 %	-0.03 %	-10.19 %	-49.95 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-53	-50	-49	-55	-62
Return On Assets (TTM)	-40.88 %	-55.75 %	-58.65 %	-65.96 %	-71.46 %
STTK's Total Ranking	# 3987	# 4684	# 4178	# 4277	# 4346
Total Assets (TTM) in million	221	102	91	100	64
Seq. Total Assets Change	116.3 %	12.19 %	-9.28 %	55.87 %	-16.58 %
Seq. Net Income Change	-	-	-	-	-

STTK's 5 Years Annual ROA >> Back to STTK Management Effectiveness >> Compare STTK ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 198
Sector	# 496
Overall	# 3767

Return On Assets Statistics
High	Average	Low
119.34 %	-154.95 %	-1175.22 %
(Nov 30 2015)		(May 31 2017)

News about Shattuck Labs Inc Return on Assets ROA

Pioneering Advancements in Biotech: Shattuck Labs’ Strategic Innovations in Targeting Immune Responses and Cancer Pathways

Shattuck Labs: Pioneering Advancements in Targeting Immune Responses and Cancer PathwaysIn the ever-evolving landscape of biotechnology, Shattuck Labs, Inc. (NASDAQ: STTK) stands as a beacon of innovation, committed to developing novel therapeutics for inflammatory and immune-related diseases. Headquartered in Austin, Texas, with facilities in Durham, North Carolina, the company recently updated stakeholders on its operational progress and outlined key milestones anticipated for 2025. This announcement not only underscores Shattuck s commitment to addressing unmet medical needs but also highlights its strategic focus on transformative therapies for complex conditions such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).At the forefront of Shattuck’s innovative pipeline is the recently unveiled SL-325, a first-in-class Death Receptor 3 (DR3) antagonist that aims to disrupt the TL1A/DR3 signaling pathway. This pathway is receiving increased scrutiny due to its pivotal role in regulating immune responses and its implication in various inflammatory disorders and cancer pathophysiology. By modulating this signaling route, Shattuck Labs seeks to provide therapeutic options for patients grappling with the complexities of diseases associated with cytokine signaling aberrations.

Financial Statements
Shattuck Labs Inc 's Assets	$ 221 million	STTK's Balance sheet
Shattuck Labs Inc 's Income	$ -15 million	Quarterly STTK's Income Statement
STTK's Income by Division		See STTK's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-0.03 %	-57.2 %	3.61 %	-31.23 %	-14.44 %
Total Assets in million	91	91	213	205	299
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-49	-75	-87	-102	-45
Annual Return On Assets	-53.62 %	-82.82 %	-41.03 %	-49.65 %	-15.06 %

STTK's 5 Years Annual ROA >> Back to STTK Management Effectiveness >> Compare STTK ROA to its Competitors

More Return On Assets Ratios
STTK's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
STTK's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for STTK's Competitors
Subscribers only: Roa for Shattuck Labs Inc 's Suppliers
Subscribers only: Return On Assets for STTK's Customers

You may also want to know
STTK's Roi	STTK's Inventory Turnover Ratio	STTK's Growth Rates	STTK's Dividend Comparisons
	STTK's Profitability Ratios	STTK's Asset Turnover Ratio	STTK's Dividend Growth
STTK's Roe	STTK's Valuation Ratios	STTK's Financial Strength Ratios	STTK's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-04T10:46:56+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.